- Home
- HYNE vs KLRS Comparison
HYNE vs KLRS Comparison
Compare HYNE & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HYNE | KLRS |
|---|---|---|
| Founded | 2025 | 2019 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.5M | 132.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HYNE | KLRS |
|---|---|---|
| Price | $15.25 | $6.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 39.1K | ★ 76.6K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.56 | $2.14 |
| 52 Week High | $16.14 | $11.88 |
Technical Indicators
Market Signals| Indicator | HYNE | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 59.58 | 43.02 |
| Support Level | $14.06 | $4.35 |
| Resistance Level | N/A | $7.18 |
| Average True Range (ATR) | 0.45 | 0.63 |
| MACD | 0.03 | 0.15 |
| Stochastic Oscillator | 67.88 | 51.32 |
Price Performance
Historical ComparisonAbout HYNE Hoyne Bancorp Inc.
Hoyne Bancorp Inc is a holding company that conducts business mainly through its subsidiaries. It is a savings institution focused on serving customers' banking needs in the market area. The group offers Personal and Business banking services.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.